🚀 VC round data is live in beta, check it out!
Weigao Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Weigao Group and similar public comparables like SonoScape, VCANBIO, Cofoe Medical, Tandem Diabetes Care and more.
Weigao Group Overview
About Weigao Group
Shandong Weigao Orthopaedic Device Co Ltd is engaged in the research and development, production and sales of orthopedic medical devices.
Founded
2005
HQ
Employees
N/A
Website
Financials (FY)
EV
$1B
Weigao Group Financials
Weigao Group reported last fiscal year revenue of $221M and EBITDA of $57M.
In the same fiscal year, Weigao Group generated $143M in gross profit, $57M in EBITDA, and $39M in net income.
Revenue (LTM)
Weigao Group P&L
In the most recent fiscal year, Weigao Group reported revenue of $221M and EBITDA of $57M.
Weigao Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $221M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $143M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 65% | XXX | XXX | XXX |
| EBITDA | — | XXX | $57M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 21% | XXX | XXX | XXX |
| Net Profit | — | XXX | $39M | XXX | XXX | XXX |
| Net Margin | — | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Weigao Group Stock Performance
Weigao Group has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Weigao Group's stock price is $4.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | -0.2% | XXX | XXX | XXX | $0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWeigao Group Valuation Multiples
Weigao Group trades at 6.4x EV/Revenue multiple, and 24.7x EV/EBITDA.
EV / Revenue (LTM)
Weigao Group Financial Valuation Multiples
As of April 5, 2026, Weigao Group has market cap of $2B and EV of $1B.
Equity research analysts estimate Weigao Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Weigao Group has a P/E ratio of 42.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 24.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 30.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 9.8x | XXX | XXX | XXX |
| P/E | — | XXX | 42.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 25.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Weigao Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Weigao Group Margins & Growth Rates
Weigao Group's revenue in the last fiscal year grew by 5%.
Weigao Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 16% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Weigao Group Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SonoScape | XXX | XXX | XXX | XXX | XXX | XXX |
| VCANBIO | XXX | XXX | XXX | XXX | XXX | XXX |
| Cofoe Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Tandem Diabetes Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunocore Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Weigao Group M&A Activity
Weigao Group acquired XXX companies to date.
Last acquisition by Weigao Group was on XXXXXXXX, XXXXX. Weigao Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Weigao Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialWeigao Group Investment Activity
Weigao Group invested in XXX companies to date.
Weigao Group made its latest investment on XXXXXXXX, XXXXX. Weigao Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Weigao Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Weigao Group
| When was Weigao Group founded? | Weigao Group was founded in 2005. |
| Where is Weigao Group headquartered? | Weigao Group is headquartered in China. |
| Is Weigao Group publicly listed? | Yes, Weigao Group is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Weigao Group? | Weigao Group trades under 688161 ticker. |
| When did Weigao Group go public? | Weigao Group went public in 2021. |
| Who are competitors of Weigao Group? | Weigao Group main competitors are SonoScape, VCANBIO, Cofoe Medical, Tandem Diabetes Care. |
| What is the current market cap of Weigao Group? | Weigao Group's current market cap is $2B. |
| What is the current revenue of Weigao Group? | Weigao Group's last fiscal year revenue is $221M. |
| What is the current EV/Revenue multiple of Weigao Group? | Current revenue multiple of Weigao Group is 6.4x. |
| Is Weigao Group profitable? | No, Weigao Group is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.